课题基金 / 基金详情

Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses

Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses
描述 LDL 相关受体 1 (Lrp1) 作为多种布尼亚病毒宿主进入因子的作用
批准号:
10667857
负责人:
Gaya K. Amarasinghe
金额:
$78.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-14 至 2028-02-29
关键词:
AddressAffinityAnimalsAtherosclerosisBindingBiochemicalBiochemistryBiologicalBiologyBioterrorismBirdsBrainBrazilBunyaviralesCategory A pathogenCell LineCellsChikungunya feverChildhoodCollaborationsComplementComplexCoupledCulicidaeDataDengueDengue FeverDiseaseDisease OutbreaksDisease OutcomeDistantDrug or chemical Tissue DistributionEmerging Communicable DiseasesEndocytosisEpidemicExcisionFamilyFamily memberFeverFrequenciesGenomicsGlycoproteinsHealthHumanHuman BiologyImmunologyIn VitroInfectionInsectaIntegration Host FactorsKidneyKnowledgeLDL-Receptor Related Protein 1La Crosse virusLigandsLipoprotein ReceptorLiverLow Density Lipoprotein ReceptorLow-Density LipoproteinsMalignant NeoplasmsMammalsMolecularMusNational Institute of Allergy and Infectious DiseaseNatureNeurodegenerative DisordersNorth AmericaOropouche virusOrthobunyavirusPathogenesisPeripheralPharmacotherapyPlayProductivityProteinsProteomicsReceptor CellReportingReptilesResearch PersonnelRift Valley fever virusRoleRouteSequence HomologySouth AmericaSpleenStructureTaxonomyTestingTherapeuticTissuesTropismUnited StatesVaccinesValidationViralViral EncephalitisViral PathogenesisVirusVirus DiseasesVirus ReplicationWorkarboviral diseasearthropod-bornechikungunyaclimate changeepidemic preparednessglobal healthhuman diseasehuman pathogenin vivoinnovationmembermouse modelnew therapeutic targetnovelpandemic potentialpathogenpreventprogramsreceptorstructural biologytherapeutic developmentvalidation studiesvector tickviral transmissionvirologyvirus tropism

项目摘要

项目成果

Gaya K. Amarasinghe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Bunyaviruses (Order: Bunyavirales) are a growing and diverse family of animal and human pathogens with pandemic potential. With over 300 members and an expanding distribution of mosquito and tick vectors due to climate change, these viruses are responsible for increasing outbreaks of human disease and present a significant threat to human health. Rift Valley Fever virus (RVFV) is one of the well-studied bunyaviruses and is designated as an NIAID Category A pathogen and included in the WHO’s Blueprint of Priority Diseases. The Coalition for Epidemic Preparedness Innovations (CEPI) included RVFV as part of their emerging infectious diseases vaccine program, further emphasizing the potential impact on the global health and economy. Oropouche virus (OROV) is found in South America and has caused more than 30 large epidemics resulting in over 500,000 human cases, making it the second most common arboviral disease in South America behind Dengue fever. However, the true case number is likely much higher due to Oropouche fever being misdiagnosed as Chikungunya or Dengue. A third member, La Crosse virus (LACV) is found primarily in North America and is the primary cause of pediatric viral encephalitis in the United States. Neither OROV nor LACV have been as well studied as RVFV, and thus a significant gap remains in our broad understanding of bunyavirus pathogenesis. Currently there are no approved therapeutic drugs for treatment of RVFV, OROV, or LACV disease, further highlighting the need for our proposed studies. To address this need, we conducted a genomic screen that defined several critical factors, including Lrp1, an LDL family member. In support we provide compelling preliminary data including in vitro validation in Lrp1 sufficient and deficient cells, transcomplementation studies, and direct interaction between RVFV glycoprotein Gn in vitro. We also show that inhibition of Lrp1 by endogenous ligands in vitro in multiple cell lines from evolutionarily distinct hosts, and in vivo data demonstrating the importance of Lrp1 for viral tropism and disease in mice. Here we will characterize the importance of Lrp1 for entry of multiple bunyaviruses, define molecular mechanisms, and validate the significance in vitro and in vivo. This work will be performed by highly productive and collaborative investigators with expertise in every aspect of the proposed studies, including biochemistry, viral pathogenesis, immunology, proteomics, structural biology, and virology. At completion, we expect to validate Lrp1 as pan-bunyavirus entry factor, filling a key gap in the field and to provide novel targets for therapeutic development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.
  • 批准号:
    10753347
  • 项目类别:
  • 资助金额:
    $24.77万
  • 财政年份:
    2023
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
  • 批准号:
    10683329
  • 项目类别:
  • 资助金额:
    $27.21万
  • 财政年份:
    2022
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
  • 批准号:
    10481430
  • 项目类别:
  • 资助金额:
    $29.65万
  • 财政年份:
    2022
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
  • 批准号:
    10375591
  • 项目类别:
  • 资助金额:
    $74.2万
  • 财政年份:
    2021
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
海外基金